Fresh from announcing a deal to acquire the USA's Rebiotix Inc. and moving into the microbiome drug development space, Ferring Pharmaceuticals AS is also targeting the hot area of gene therapy with a late-stage licensing deal for a novel bladder cancer treatment from Finland's FKD Therapies OY.
Ferring Makes Foray Into Gene Therapy With FKD Pact
The Swiss company's CMO Klaus Dugi tells Scrip that getting the rights to a late-stage bladder cancer gene therapy from Finland's FKD highlights the transformation that Ferring is undergoing.
More from Anticancer
More from Therapy Areas
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.